Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Feb;47(2):116–126. doi: 10.1136/ard.47.2.116

Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

K Hørslev-Petersen 1, K D Bentsen 1, A Engström-Laurent 1, P Junker 1, P Halberg 1, I Lorenzen 1
PMCID: PMC1003463  PMID: 3355249

Abstract

Increased serum levels of the amino terminal type III procollagen peptide and serum hyaluronan were demonstrated in patients with rheumatoid arthritis. In patients with active disease a significant correlation was shown between serum levels of the propeptide and hyaluronan and the clinical signs of synovitis reflecting the extent of synovial inflammation. During recovery the serum propeptide and serum hyaluronan showed a delayed decline as compared with the clinical signs of synovitis and the acute phase protein response. This probably reflects the presence of persistent subclinical chronic inflammation. Normal serum propeptide levels in rheumatoid arthritis were associated with a good prognosis without progression of erosive joint lesions. Azathioprine reduced the number of patients with progression of erosive joint lesions and caused a more marked suppression of the serum propeptide than levamisole and penicillamine.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballardini G., Faccani A., Bianchi F. B., Fallani M., Patrono D., Capelli M., Pisi E. Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procollagen III peptide, in chronic liver disease. Liver. 1984 Dec;4(6):348–352. doi: 10.1111/j.1600-0676.1984.tb00950.x. [DOI] [PubMed] [Google Scholar]
  2. Bentsen K. D., Hørslev-Petersen K., Junker P., Juhl E., Lorenzen I. Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study. Liver. 1987 Apr;7(2):96–105. doi: 10.1111/j.1600-0676.1987.tb00324.x. [DOI] [PubMed] [Google Scholar]
  3. Bentzon M. W., Gad I., Halberg P., Halskov O., Jacobsen B. K., Lorenzen I., Morling N., Svejgaard A. Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis. Clin Rheumatol. 1986 Jan;5(1):39–48. doi: 10.1007/BF02030966. [DOI] [PubMed] [Google Scholar]
  4. Dorner R. W. Scleroderma skin--conflicting mucopolysaccharide data reflect stages in connective tissue maturation. J Rheumatol. 1980 Mar-Apr;7(2):128–129. [PubMed] [Google Scholar]
  5. Engström-Laurent A., Feltelius N., Hällgren R., Wasteson A. Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells? Ann Rheum Dis. 1985 Sep;44(9):614–620. doi: 10.1136/ard.44.9.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Engström-Laurent A., Laurent U. B., Lilja K., Laurent T. C. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest. 1985 Oct;45(6):497–504. doi: 10.3109/00365518509155249. [DOI] [PubMed] [Google Scholar]
  7. Gay S., Gay R. E., Miller E. F. The collagens of the joint. Arthritis Rheum. 1980 Aug;23(8):937–941. doi: 10.1002/art.1780230810. [DOI] [PubMed] [Google Scholar]
  8. Hahn E. G. Blood analysis for liver cirrhosis. J Hepatol. 1985;1(1):67–73. doi: 10.1016/s0168-8278(85)80069-6. [DOI] [PubMed] [Google Scholar]
  9. Halberg P., Bentzon M. W., Crohn O., Gad I., Halskov O., Heyn J., Ingemann M., Junker P., Lorenzen I., Møller I. Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis. Clinical, biochemical, radiological and scintigraphic studies. Dan Med Bull. 1984 Oct;31(5):403–409. [PubMed] [Google Scholar]
  10. Hatahara T., Igarashi S., Funaki N. High concentrations of N-terminal peptide of type III procollagen in the sera of patients with various cancers, with special reference to liver cancer. Gan. 1984 Feb;75(2):130–135. [PubMed] [Google Scholar]
  11. Hørslev-Petersen K., Bentsen K. D., Junker P., Lorenzen I. Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions. Arthritis Rheum. 1986 May;29(5):592–599. doi: 10.1002/art.1780290503. [DOI] [PubMed] [Google Scholar]
  12. Ingeman-Nielsen M., Halskov O., Hansen T. M., Halberg P., Stage P., Lorenzen I. Clinical synovitis and radiological lesions in rheumatoid arthritis. A prospective study of 25 patients during treatment with remission-inducing drugs. Scand J Rheumatol. 1983;12(3):237–240. doi: 10.3109/03009748309098540. [DOI] [PubMed] [Google Scholar]
  13. Jans H., Halberg P., Lorenzen I. Circulating immune complexes in rheumatoid arthritis with extra-articular manifestations. Scand J Rheumatol. 1983;12(3):215–218. doi: 10.3109/03009748309098536. [DOI] [PubMed] [Google Scholar]
  14. Krieg T., Langer I., Gerstmeier H., Keller J., Mensing H., Goerz G., Timpl R. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol. 1986 Dec;87(6):788–791. doi: 10.1111/1523-1747.ep12459865. [DOI] [PubMed] [Google Scholar]
  15. Larsen A., Dale K., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. doi: 10.1177/028418517701800415. [DOI] [PubMed] [Google Scholar]
  16. Lovell C. R., Nicholls A. C., Jayson M. I., Bailey A. J. Changes in the collagen of synovial membrane in rheumatoid arthritis and effect of D-penicillamine. Clin Sci Mol Med. 1978 Jul;55(1):31–40. doi: 10.1042/cs0550031. [DOI] [PubMed] [Google Scholar]
  17. McCullough A. J., Stassen W. N., Wiesner R. H., Czaja A. J. Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology. 1987 Jan-Feb;7(1):49–54. doi: 10.1002/hep.1840070112. [DOI] [PubMed] [Google Scholar]
  18. Myllylä G., Vaheri A., Penttinen K. Detection and characterization of immune complexes by the platelet aggregation test. II. Circulating complexes. Clin Exp Immunol. 1971 Mar;8(3):399–408. [PMC free article] [PubMed] [Google Scholar]
  19. Nordfang O., Høier-Madsen M., Halberg P., Lieberkind J. A new radioimmunoassay for IgM and IgG rheumatoid factors, based on a double antibody method. J Immunol Methods. 1981;47(1):87–97. doi: 10.1016/0022-1759(81)90259-3. [DOI] [PubMed] [Google Scholar]
  20. Rohde H., Langer I., Krieg T., Timpl R. Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments. Coll Relat Res. 1983 Sep;3(5):371–379. doi: 10.1016/s0174-173x(83)80018-1. [DOI] [PubMed] [Google Scholar]
  21. Rohde H., Vargas L., Hahn E., Kalbfleisch H., Bruguera M., Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest. 1979 Dec;9(6):451–459. doi: 10.1111/j.1365-2362.1979.tb00912.x. [DOI] [PubMed] [Google Scholar]
  22. Savolainen E. R., Miettinen T. A., Pikkarainen P., Salaspuro M. P., Kivirikko K. I. Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis. Gut. 1983 Feb;24(2):136–142. doi: 10.1136/gut.24.2.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weigand K., Zaugg P. Y., Frei A., Zimmermann A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology. 1984 Sep-Oct;4(5):835–838. doi: 10.1002/hep.1840040506. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES